New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer

NeoPhore, has received investment from Sixth Element Capital to develop small molecules that stimulate the immune system against cancer.

Sixth Element Capital has invested £3M (€3.3M) in NeoPhore, a new spin-out from PhoreMost – a drug discovery company based in Cambridge, UK. NeoPhore has been set up to explore small molecules that could be used to stimulate the immune system to fight cancer. It will be asset-centric, meaning it will focus on drug development and reducing financial risk. The spin-out will use the investment to build on discoveries made by PhoreMost and its collaborators.

NeoPhore hopes to exploit biological mechanisms to stimulate the creation of cancer antigens that will boost cancer immunity in patients with unresponsive “cold” tumors and improve patient response to other immunotherapies. The spin-out has remained loyal to small molecules despite a number of companies like Boehringer Ingelheim turning their backs on the field and focusing on other technology like monoclonal antibodies. It won’t be too lonely though, with Karus Therapeutics also working on small molecules.

Image – Pigprox /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.